Downregulating the leukocyte adhesion molecules expressed by endothelial cells which line tumor blood vessels can limit the entry of immune effector cells into the tumor mass, thereby contributing to tumoral immune escape. Egfl7 (also known as VE-statin) is a Human breast cancer lesions expressing high levels of Egfl7 also expressed less ICAM-1 and VCAM-1 in their blood vessels, also indicating an inverse correlation between expression levels of Egfl7 and interferon-Ȗ. Thus, Egfl7 expression in tumors promotes tumor progression by reducing the expression of endothelial molecules that mediate immune cell infiltration. Our findings highlight a novel mechanism through which tumors escape immune control.
Introduction
Blood vessels are essential for the growth of most solid tumors and for metastasis.
Within a tumor, new blood vessels, formed mostly by endothelial cells, sustain the nutriment and oxygen supplies of the developing mass (1) . The tumor endothelium forms an imperfect, tortuous, and leaky barrier (2) . Metastatic cells enter the blood circulation through this endothelium (intravasation) and spread across the organism as an alternative route to lymphatic metastasis (3) (4) (5) . On the other hand, infiltration of circulating immune cells, such as natural killer (NK) cells and CD8 + cytotoxic T-lymphocytes, into the tumor mass plays a part in the control of tumor growth through interferon-Ȗ (IFNg) and cytotoxic-based mechanisms (6) (7) (8) (9) . In order to destroy tumor cells, circulating immune cells must first infiltrate the tumor mass. The tumor blood vessel endothelium, although imperfectly tight, actively protects tumor cells from the immune system through its barrier function. The transmigration of leukocytes through the endothelium is a normal process which, during inflammation, results in the infiltration of circulating cells from the blood stream into tissues. Such extravasation depends on a complex set of interactions between leukocytes and endothelial membrane receptors which, on the endothelial side, involves E-and P-selectin, ICAM-1, VCAM-1 and PECAM/CD31 as the main actors (10) . Tumor escape from immunity may be achieved by preventing infiltration of effector immune cells (11) through the down-regulation of these endothelial adhesion molecules (12) (13) (14) (15) .
We originally characterized Egfl7 (VE-statin) as a gene specifically expressed by blood vessel endothelial cells in normal organs during development and in the adult (16, 17) . In human cancer, this specificity of expression is lost as Egfl7 has been detected in tumor cells themselves, in addition to endothelial cells. Its expression levels correlate with a higher tumor grade in glioma (18) and colon cancer patients (19) , and with a poorer prognosis and higher metastatic score in hepatocarcinoma patients (20) . Although these observations suggested a role for Egfl7 in cancer progression, its direct role in tumor development has not been studied yet. Here, we show that Egfl7 is an endogenous regulator of endothelial cell activation which, when expressed by tumor cells, protects the tumor from the host immunity. Cloning. The mouse Egfl7 cDNA was cloned in frame with a C-terminal influenza hemagglutinin (HA)-coding sequence in the pMSCV plasmid (Clontech), allowing the production of retrovirus after transfection in HEKGP cells. 4T1 and LLC1 cells were infected with control or Egfl7-coding viruses and whole cell populations were selected for puromycin resistance (4μg/ml) for 7 days. Tumor vessel perfusion. Blood vessel leakage was assessed by injecting 100μl of PBS, 0.5mg/ml Lycopersicon esculentum lectin-FITC (Vector Laboratories) and 2.5mg/ml Dextran (70kD)-Texas Red (Molecular Probes) in the tail vein. Mice were euthanized after 10min, and tumors were collected and processed for cryosection. Hypoxia was estimated after peritoneal injection of 0.15M NaCl, 60mg/kg pimonidazole-HCl (Hypoxyprobe, HPI). Mice were sacrificed after 30min, tumors were collected, proceeded for paraffin inclusion, and hypoxyprobe detected by immunohistochemistry.
Immunohistochemistry. Tumors were either fixed in 4% paraformaldehyde, embedded in paraffin and sectioned (7μm) or frozen in OCT compound, sectioned at 10μm and post-fixed with 1% paraformaldehyde (5min). Immunostainings were performed using antibodies as listed in Table S1 . For necrosis analysis, sections were stained with haematoxylin/eosin and necrotic areas identified as unstained regions. Apoptotic cells were visualized using the Terminal Transferase recombinant kit (Roche). Proliferating cells were detected by staining with a Ki67 antibody (Roche). For optical microscopy, sections were counterstained with haematoxylin. For immunofluorescence microscopy, cell nuclei were labeled by incubating in DAPI solution (1 μg/ml, Sigma) for 1min at room temperature. Slides were analyzed using an Axioplan2 or an AxioImagerZ1 microscope (Zeiss) and the AxioVs V4.8.2.0 software or a confocal LSM710 microscope (Zeiss) using the ZEN2008 software (MICPaL, Lille). Angiogenic hotspots were analyzed by image analysis of CD31-stained sections using the ImageJ v1.42q software (22) .
Tumor endothelial cell isolation.
Freshly collected tumors (n=6/group) were minced and dissociated in DMEM, 1mg/ml collagenase-I, 10μg/ml DNase-I for 30min at 37°C and filtered (90μm and 40μm mesh). Cells from each tumor were treated separately. Cells were incubated in red blood cell lysis buffer and IL12p40 were quantified in the supernatants by ELISA (BD-Biosciences). For NK cell function, mouse liver mononuclear cells were labeled with APC-conjugated anti-CD5 and PEconjugated anti-NK1.1 mAbs. CD5 -/NK1.1 + cells were sorted using a FACSAria (BD Biosciences), cultured in RMPI/5% FCS (10 4 cells/well) and stimulated with 10ng/ml IL12 and 10ng/ml IL18 in the presence or not of 150ng/ml rEgfl7 for 48h. IFNg production was analyzed in supernatants by ELISA (eBiosciences, Paris, France). T-cells were purified from spleens by negative selection using a Dynal T-cell isolation kit (Life Technologies). T-cells (10 5 cells/well)
were cultured in RPMI/5% FCS and stimulated or not with plate-bound anti-CD3 (5μg/ml) and soluble anti-CD28 (1μg/ml), in the presence or not of 150ng/ml rEgfl7 for 48h. IFNg production was analyzed in supernatants by ELISA. Proliferation was assessed 96h later, using
AlamarBlue (Life technologies).
Human tumor samples.
Human tumors were collected, processed and stored at the anatomo-pathology laboratory of the Centre Oscar Lambret, Lille, France. Tissues were fixed in 4% paraformaldehyde (Prolabo) and embedded in paraffin. Sections (4μm) were stained using a polyclonal anti-hEgfl7 antibody 
RESULTS

Egfl7 promotes tumor growth and metastasis
In order to study the potential role of Egfl7 in tumor development, mouse 4T1 breast cancer cells were infected with a retrovirus encoding the full length, HA-tagged, mouse Egfl7 (4T1-Egfl7) or with a control virus (4T1-Ctrl). When implanted into the mammary fat pad of syngeneic Balb/c mice, 4T1-Egfl7 cells formed tumors which showed a marked accumulation of Egfl7 (Fig. 1A, B) . These tumors grew much faster in volume than 4T1-Ctrl tumors and, accordingly, the mean final weight of 4T1-Egfl7 tumors was twice as high as that of 4T1-Ctrl tumors (Fig. 1C) . Mice bearing 4T1-Egfl7 tumors also had a 3.6-times higher frequency of lung metastasis when compared to 4T1-Ctrl tumors (Fig. 1D) . Since in vivo experiments can vary with the cell lines and animal models used, we performed similar experiments using the LLC1 lung carcinoma cell line implanted in syngeneic C57BL/6 mice. LLC-Egfl7 cells also produced tumors that grew faster than LLC-Ctrl (Fig. 1E) . The effects of Egfl7 on tumor growth and metastasis in vivo were not due to intrinsic modifications of the tumor cell properties since expression of Egfl7 had no effects on 4T1 and LLC1 proliferation, migration, or clone formation in anchorage-independent conditions in vitro (Fig. S1) .
In vivo, 4T1-Egfl7 tumors displayed larger necrotic areas than 4T1-Ctrl tumors ( Fig. 2A) and a similar tendency was observed in LLC1 tumors. Hypoxia was higher in 4T1-Egfl7 tumors than controls (Fig. 2B) whereas the apoptosis, cleaved caspase-3 levels and Ki67 proliferation indexes were comparable between tumors (Fig. S2) . Microvessel density in angiogenic hotspots was slightly increased in 4T1-Egfl7 tumors when compared to controls, but was not significantly different between LLC1 tumors (Fig. 2C) . Interestingly, 4T1-Egfl7 tumor blood vessels were much more permeable than 4T1-Ctrl vessels (Fig. 2D) , and although excessive edema was not observed, blood lakes were more frequent in LLC-Egfl7 tumors than in LLC-Ctrl tumors (2.7% +/-0.93 and 1.1% +/-0.4 of the tumor area, respectively).
Egfl7-expressing tumors are less infiltrated by immune cells.
Interestingly, a detailed observation revealed the presence of numerous small round cells in the lumen of 4T1-Egfl7 tumor blood vessels, whereas these cells were less frequently observed within the tumor tissue itself. In contrast, 4T1-Ctrl tumors had very few cells accumulated in their blood vessels and the tumor tissue appeared more granular than 4T1-Egfl7 tumors (Fig. 3A) . Since these cells resembled circulating or infiltrated immune cells, staining for the blood vessels (Fig. 3B) . Staining for CD4 + and CD8 + cells showed that both T-cell populations were affected, with a 42% and 45% decrease in the respective number of cells infiltrated in 4T1-Egfl7 tumors, when compared to 4T1-Ctrl (Fig. 3C, Fig. S3 ). These effects
were not restricted to the T-cell lineage as the numbers of infiltrated B-lymphocytes (CD19 (Fig. 3C, Fig. S3 ). This correlated with large differences in the transcript levels of immune-stimulating cytokines IFNg and IL12b, and, to a lower extent, IL1a, and IL1b, which levels were strongly reduced in 4T1-Egfl7 tumors when compared to controls (Table S2) . Similar results were obtained using the LLC-C57BL/6 model; LLC-Egfl7 tumors expressed much less CD3E and IFNg transcripts than LLC-Ctrl tumors (Table S3) 
, suggesting that the immune depletion was not systemic in mice carrying 4T1-Egfl7 tumors but was locally restricted to the tumor tissue (Fig. S4) .
Altogether, these results show that 4T1-Egfl7 tumors formed a local immune-deficient environment.
The effects of Egfl7 on tumor growth depend on the immune system
In order to directly assess the importance of the host immune system on the effects of Egfl7, 4T1-Ctrl and 4T1-Egfl7 cells were injected in the mammary gland of immunosuppressed SCID-beige mice, which lack functional T-, B-, and NK cells. As expected, 4T1-Ctrl tumors grew much faster and induced a higher rate of metastasis in SCID-beige mice when compared to Balb/c immunocompetent mice (Fig. 4) , thus confirming the repressing effects of immune cells on tumor development. On the other hand, expression of Egfl7 in tumor cells failed to accelerate tumor growth and metastasis in SCID-beige mice so that no differences between the growth rates of 4T1-Ctrl and 4T1-Egfl7 tumors could be seen.
Thus, the effects of Egfl7 on tumor growth and metastasis depend on an active host immune system.
Egfl7 represses leukocyte adhesion molecules in tumor endothelial cells
We next addressed the potential effects of Egfl7 on the functions of immune cells. rEgfl7, which was active as an inhibitor of PDGF-BB-induced smooth muscle migration (Fig S5A, (16,   23) ), had no effect on the LPS-induced release of IL6 (Fig. 5A) and IL12p40 (Fig. S5B) 
dendritic cells. Similarly, rEgfl7 did not affect IFNg production by NK cells stimulated with IL12 and IL18 and failed to modulate the anti-CD3/anti-CD28-stimulated production of IFNg (Fig. 5A) as well as their proliferation (Fig. S5B) .
We thus investigated whether Egfl7 could alter the recruitment of immune cells within the tumors. Expression of cell adhesion molecules such as E-and P-selectins, ICAM-1, VCAM-1 and CD31/PECAM by endothelial cells plays a crucial role in leukocyte rolling and adhesion before trans-endothelial migration (10) . We detected high levels of expression of ICAM-1 and VCAM-1 in 4T1-Ctrl tumor blood vessels whereas expression was weak in 4T1-Egfl7 tumors (Fig. 5B) . To confirm this, CD45
-/CD31 + endothelial cells from tumors were isolated. In agreement with the immunostainings, the expression levels of ICAM-1 and VCAM-1 in endothelial cells purified from 4T1-Egfl7 tumors were reduced by 57% and 70%, respectively, when compared to controls (Fig. 5C ). Endothelial cells isolated from 4T1-Egfl7 tumors also expressed much lower levels of E-selectin (Fig. 5D) . These results provide a likely explanation for the observed deficit of immune cells and cytokines within 4T1-Egfl7 tumors. In addition, endothelial genes involved in promoting vessel integrity, maturation, and quiescence such as Tie-2 and PAI-1 were repressed by more than 80% in endothelial cells of 4T1-Egfl7 tumors whereas expression of uPA was increased in these cells (Fig. 5D) . Expression of Dll4 was strongly repressed, in agreement with the observed increased vascular density and hypoxia, but in apparent contradiction with the enhanced tumor development (24) . Of note, flt-1 expression was strongly increased in 4T1-Egfl7 tumor endothelial cells and the expression levels of CD31/PECAM, P-selectin, VE-cadherin, eNOS, and of the integrin sub-units Įv, Į3, ȕ1 and ȕ3
were not modified (not shown).
Altogether, these results suggest that the decreased frequency of immune cells within 4T1-Egfl7 tumors is rather due to the inhibition of their recruitment rather than to the repression of their functions, and corresponds to phenotypic modifications of the endothelium.
Egfl7 directly regulates leukocyte adhesion on endothelial cells
The possibility that Egfl7 directly affects the expression of leukocyte adhesion molecules by endothelial cells was studied in vitro using the Jurkat T-cell lymphoma model of immune cell adhesion on human primary HUVEC endothelial cells, a model known to depend on ICAM-1 and VCAM-1 (25) . Treatment of HUVEC with medium conditioned by 4T1-Egfl7 cells reduced the number of T-lymphocytes adhering onto the endothelial monolayer by half when compared to cells incubated with a medium conditioned by 4T1-Ctrl cells (Fig. 6A) . Repressing the endogenous egfl7 gene in endothelial cells using RNA interference (Fig. S6A) number of T-lymphocytes adhering to HUVEC when compared to control (Fig. 6B) . This correlated with a large increase in expression of E-selectin, Vcam-1, and Icam-1 transcripts while expression of P-selectin and CD31/PECAM was not affected (Fig. 6C) . Further, repressing either Icam-1 or Vcam-1 (Fig. S6B, C) in endothelial cells treated with a siRNA targeting Egfl7 reduced the effects of this latter siRNA on T-cell adhesion (Fig. 6D) , suggesting that the repressing effects of Egfl7 on depend directly on the repression of Icam-1 and Vcam-1.
Expression of ICAM-1, VCAM-1 and IFNg is repressed in human tumors expressing Egfl7
In order to validate our observations in human cancers, expression of ICAM-1, VCAM-1 and IFNg was analyzed in a series of human breast carcinomas which were selected on the basis of their expression levels of Egfl7 in tumor cells (GLP, FS, personal communication).
Within the same lesion, there was a 23% and 13% decrease in the numbers of blood vessels expressing ICAM-1 and VCAM-1, respectively, when these vessels were in close vicinity to tumor cells expressing high levels of Egfl7, when compared to areas where expression of Egfl7 was low (peritumoral, Fig. 7A, B) . Furthermore, the levels of expression of IFNg were inversely correlated to the levels of expression of egfl7 measured in a series of human breast tumor samples (Fig. 7C) . 
Discussion
We show here that Egfl7 is a natural repressor of endothelial cell activation. It inhibits the expression of endothelial adhesion molecules, and consequently reduces the adhesion of lymphocytes onto the endothelium. When placed in a tumor context, these effects result in an increased escape from immunity and a more rapid tumor growth.
The few previous studies that have described the expression of Egfl7 in human cancers all suggested that Egfl7 could promote tumor growth and metastasis (18) (19) (20) The down-regulation of endothelial adhesion molecules in tumors (12) (13) (14) (15) and in human cancers (12, 14, 26) had already been observed. Egfl7 might favor tumor escape from immunity by down-regulating the expression of endothelial adhesion molecules, although the mechanisms are still elusive. Of note, Egfl7 was recently reported to down-regulate the NF-țB pathway in human coronary artery endothelial cells after an ischemia/reoxygenation treatment (27) . Based on this observation and our results, it is thus possible that a direct repression of the NF-kB pathway by Egfl7 in endothelial cells contributes to the repression of ICAM-1 and, possibly, that of VCAM-1 and E-selectin.
We also observed that expression of Egfl7 in tumors increases blood vessel permeability and decreases expression of Tie-2 when compared to controls, suggesting that the endothelium integrity is altered in the presence of Egfl7. Since Egfl7 was shown to inhibit PDGF-BB-induced 
smooth muscle cell migration (16) , it is likely that its expression prevents the recruitment of perivascular cells to newly formed tumor blood vessels, thus decreasing vascular tightness.
Such a lack of vessel integrity is commonly observed in tumors (2) and is proposed to favor tumor spreading through metastasis (4, 28) . Interestingly, overexpression of angiopoietin-2 in tumors also increases vessel permeability but correlates with a higher rate of immune cell infiltration within the primary tumors, and with a reduced tumor growth rate (29) . Altogether, these observations suggest that, depending on the conditions, the disruption of the endothelium might lead both to a reduced primary tumor and to an increase in metastasis which could explain the observed dual anti-primary tumor/pro-metastatic effects of anti-angiogenic therapies (30, 31) .
In human breast tumor cells, we observed that expression of Egfl7 corresponds to a local decrease in ICAM-1 and VCAM-1 expression in adjacent blood vessels, whereas more distant vessels are not affected. This suggests that Egfl7 has similar local effects on blood vessels in human tumors to those observed in experimental tumors in mice. The inverse correlation between the expression levels of Egfl7 in human tumors and those of IFNg further validates our hypothesis and suggests that Egfl7 produces an immune-deficient environment within human breast cancer tissues.
Tumor escape from immunity is undoubtedly an interesting process to consider for the design of therapeutic tools aimed at preventing cancer progression and metastasis. Egfl7 
